GeneralConnection.com ➔ Dictionary
Dictionary Search

ritonavir

Synonyms

Noun

1. Norvir

2. protease inhibitor, PI

Usage
A study on the stability of ritonavir form III processed in orbit and returned to Earth | npj Microgravity - Nature
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients - The New England Journal of Medicine
Nirmatrelvir-Ritonavir Significantly Lowers Risk for COVID-19-Related Hospitalization - Infectious Disease Advisor
Nirmatrelvir-Ritonavir Speeds COVID-19 Recovery but Fails to Reduce Hospitalizations in Vaccinated High-Risk Adults - Pharmacy Times
Cost-Effectiveness of Nirmatrelvir-Ritonavir Varies by COVID-19 Risk Profile - AJMC
Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency - Rockefeller University Press
The curious case of disappearing polymorphs - Chemistry World
Nirmatrelvir/Ritonavir Reduces Hospitalization, Mortality in Patients 65 Years and Older With COVID-19; Effect on Younger Patients Unclear - American Academy Of Family Physicians | AAFP
13 Things To Know About Paxlovid, the COVID-19 Pill | News - Yale Medicine
Paxlovid doesn’t reduce hospitalization, death rates in vaccinated high-risk COVID outpatients, trial shows - CIDRAP
Boceprevir Label Revised: Do Not Coadminister With Ritonavir-Boosted HIV Protease Inhibitors - Gastroenterology & Endoscopy News
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial - The Lancet
Predicting the ritonavir crisis by revisiting the polymorph landscape with crystal structure prediction and form 4 structure solution | Communications Chemistry - Nature
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients - The New England Journal of Medicine
Nirmatrelvir/Ritonavir Does Not Significantly Reduce Symptoms or Hospitalization in Vaccinated High-Risk Patients and Unvaccinated Patients - American Academy Of Family Physicians | AAFP
Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study - Nature
Should Patients with COVID-19 Who Are at Standard Risk Take Nirmatrelvir/Ritonavir? - NEJM Clinician
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study - Nature
A real-world retrospective analysis comparing the effectiveness of Azvudine and Nirmatrelvir/Ritonavir in COVID-19 patients with diabetes - Nature
Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study - Nature
Molnupiravir, Nirmatrelvir-Ritonavir Not Supported for Inpatients With COVID-19 - Vaccine Advisor
If It's COVID, Paxlovid? Studies Suggest a Rethink These Days - MedPage Today
Nirmatrelvir-Ritonavir Has Variable Impact on Incidence of Post-COVID-19 Condition - Pharmacy Times
Paxlovid speeds recovery but does not reduce severe COVID outcomes in vaccinated adults - News-Medical
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet
Based a Machine Learning Approach to Investigate the Factors Influencing Nirmatrelvir/ritonavir Exposure in Human Plasma: A Multicenter, Observational Study - Frontiers
Pharmacokinetic drug-drug interaction between the COVID-19 3CL protease inhibitor GST-HG171 and itraconazole in healthy subjects - ASM Journals
Trials demonstrate Paxlovid’s evolving role against COVID-19 - Healio
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 - The New England Journal of Medicine
Trial data show ensitrelvir has potent antiviral activity against COVID-19 - CIDRAP
Varda Deepens Drugs-in-Space Bet After Win With AIDS Medication - Bloomberg
Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19 - The New England Journal of Medicine
FDA SIDE EFFECTS UPDATE: Paxlovid And Breast Milk & More - MedShadow Foundation
Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection - Nature
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation - Nature
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 - The New England Journal of Medicine
10 Common Ritonavir Interactions You Want to Watch for - GoodRx
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients - Nature
Exploring the therapeutic mechanism of itraconazole combined with ritonavir on Candida albicans infection through network pharmacology and molecular docking - Frontiers
Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review - Frontiers
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation - Nature
Nirmatrelvir Speeds Recovery, Cuts Symptoms in COVID-19 - Medscape
Microgravity Is The Final Frontier For Medicine. Here's Why. - ScienceAlert
Complete Heart Block Triggered by Nirmatrelvir-Ritonavir and Verapamil: - JACC Journals
Paxlovid substantially reduced risk of hospitalization, death during Omicron wave - Hospital News
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial - The Lancet
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study - Nature
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV - Nature
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation - Nature
Stability indicating RP-HPLC technique for simultaneous estimation of nirmatrelvir and ritonavir in their new copackaged dosage form for COVID-19 treatment - Nature
Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial - The Lancet
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - The Lancet
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system - The Lancet
Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system - Nature
AustralaSian COVID-19 Trial (ASCOT) removes hydroxychloroquine and lopinavir/ritonavir arms of the trial - Doherty Institute
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 - Nature
Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome - The New England Journal of Medicine
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment - The New England Journal of Medicine
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19 - The New England Journal of Medicine
WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19 - World Health Organization (WHO)
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection - The New England Journal of Medicine
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: a - The Lancet
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 - The New England Journal of Medicine
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 - The New England Journal of Medicine
Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial - The Lancet
Norvir (Ritonavir) for HIV: Dosage, Side Effects, and More - TheBody
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study - Nature
The effect of nirmatrelvir-ritonavir on hospital admissions and mortality from COVID-19 - IDSA
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study - The Lancet
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients - Oxford Academic
COVID-19 Management With Paxlovid (Nirmatrelvir-Ritonavir) Effective in CKD - Vaccine Advisor
Nirmatrelvir-Ritonavir Shows No Outcome Benefit in Vaccinated High-Risk COVID-19 Patients: NEJM - Medical Dialogues
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial - The Lancet
VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 - The New England Journal of Medicine
Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing - Nature
Unexpected voriconazole toxicity due to nirmatrelvir/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring - Frontiers
Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study - Nature
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study - The Lancet
Case Report: Nirmatrelvir/Ritonavir and Tacrolimus in a Kidney Transplant Recipient With COVID-19 - American Academy Of Family Physicians | AAFP
Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations - Nature
Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies - Frontiers
Effects of Ritonavir-Boosted Darunavir vs Doravirine in Patients With HIV Infection - Infectious Disease Advisor
Dolutegravir noninferior to a ritonavir-boosted protease inhibitor regimen for treating HIV - 2 Minute Medicine
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management - The Lancet
Darunavir/Ritonavir With Rifampicin May Be Hepatotoxic - Infectious Disease Advisor
Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19 - Clinical Trials Arena
Could mechanochemistry have saved Abbott Laboratories $250 million? - Chemistry World
Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials - Nature
Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations - Nature
Dolutegravir plus darunavir superior to three-drug darunavir combination in second-line treatment - Aidsmap
Yes We Can (Use Nirmatrelvir/Ritonavir Even in High Immunological Risk Patients Treated with Immunosuppressive Drugs)! - Springer Nature Link
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19 - Frontiers
High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment - Nature
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis - Annals of Family Medicine
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 - The New England Journal of Medicine
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir - Nature
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction - ScienceDirect.com
Nirmatrelvir–Ritonavir Ineffective for Most Post-COVID Conditions - respiratory-therapy.com
Uptick in Paxlovid Shows No Clinical Benefit in Vaccinated Older Adults With COVID-19 - Vaccine Advisor
Nirmatrelvir-Ritonavir Has Little Impact on COVID-19 Hospitalization, Mortality in Vaccinated Older Adults - Pharmacy Times
Foreign Language Equivalents
Foreign Language Equivalents of 'ritonavir'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
,   ritonavit,   ritonavirr,   irtonavir,   titonavir,   rutonavir,   rironavir,   ritoonavir,   riotnavir,   rittonavir,   ritomavir,   rotonavir,   ritpnavir,   ritonnavir,   eitonavir,   ritonsvir,   rritonavir,   ritonaviir,   ritonair,   ritonavor,   ritonvair,   ritoanvir,   ritonaivr,   ritonvir,   ritonavur,   ritonavie,   ritonabir,   ritonavr,   ritnoavir,   ritonacir,   ritonavri,   rtonavir,   ritinavir,   ritoavir,   ritonavvir,   ritobavir,   ritonavi,   riyonavir,   itonavir,   rtionavir,   ritnavir,   rionavir,   ritonaavir,   riitonavir
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z